Asensus Surgical Secures Deal with Leading US Hospital

Asensus Surgical (NYSE American: ASXC) announced that a leading United States-based hospital has initiated a Senhance® Surgical System program for use within its pediatric surgery department. The company’s share price rose over 8% following the news on July 14, 2023.

Asensus expects to provide more information regarding the agreement in the next 60 days. 

Highlights

This will be the first Senhance Surgical System to be exclusively utilized by pediatric surgeons at a United States-based hospital, showcasing Senhance’s unique applicability for pediatric applications.

Anthony Fernando, Asensus Surgical President and CEO, said, “We are thrilled to collaborate and introduce our system to this prestigious pediatric surgery program. Together, we will strive to drive advancements in surgical techniques, ultimately improving the lives of children requiring surgery.”

The Senhance Surgical System leverages Augmented Intelligence and machine learning for superior surgical performance and patient outcomes. Its specialized 3mm and 5mm instruments are perfectly suited for the delicate nature of pediatric procedures.

About Asensus Surgical

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Asensus Surgical Secures Deal with Leading US Hospital

Editor Prism MarketView